Recognition and management of resistant hypertension

Branko Braam, Sandra J. Taler, Mahboob Rahman, Jennifer A. Fillaus, Barbara A. Greco, John P. Forman, Efrain Reisin, Debbie L. Cohen, Mohammad G. Saklayen, S. Susan Hedayati

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Despite improvements in hypertension awareness and treatment, 30%–60% of hypertensive patients do not achieve BP targets and subsequently remain at risk for target organ damage. This therapeutic gap is particularly important to nephrologists, who frequently encounter treatment-resistant hypertension in patients with CKD. Data are limited on how best to treat patients with CKD and resistant hypertension, because patients with CKD have historically been excluded from hypertension treatment trials. First, we propose a consistent definition of resistant hypertension as BP levels confirmed by both in-office and out-of-office measurements that exceed appropriate targets while the patient is receiving treatment with at least three antihypertensive medications, including a diuretic, at dosages optimized to provide maximum benefit in the absence of intolerable side effects. Second, we recommend that each patient undergo a standardized, stepwise evaluation to assess adherence to dietary and lifestyle modifications and antihypertensive medications to identify and reduce barriers and discontinue use of substances that may exacerbate hypertension. Patients in whom there is high clinical suspicion should be evaluated for potential secondary causes of hypertension. Evidence-based management of resistant hypertension is discussed with special considerations of the differences in approach to patients with and without CKD, including the specific roles of diuretics and mineralocorticoid receptor antagonists and the current place of emerging therapies, such as renal denervation and baroreceptor stimulation. We endorse use of such a systematic approach to improve recognition and care for this vulnerable patient group that is at high risk for future kidney and cardiovascular events.

Original languageEnglish (US)
Pages (from-to)524-535
Number of pages12
JournalClinical Journal of the American Society of Nephrology
Volume12
Issue number3
DOIs
StatePublished - Jan 1 2017

Keywords

  • Antagonists
  • Antihypertensive Agents
  • Blood pressure
  • Cardiovascular disease
  • Chronic
  • Chronic kidney disease
  • Denervation
  • Diuretics
  • Humans
  • Hypertension
  • Kidney
  • Life Style
  • Mineralocorticoid Receptor
  • Pressoreceptors
  • Renal Insufficiency
  • Renal denvervation
  • Sodium intake

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'Recognition and management of resistant hypertension'. Together they form a unique fingerprint.

  • Cite this

    Braam, B., Taler, S. J., Rahman, M., Fillaus, J. A., Greco, B. A., Forman, J. P., Reisin, E., Cohen, D. L., Saklayen, M. G., & Hedayati, S. S. (2017). Recognition and management of resistant hypertension. Clinical Journal of the American Society of Nephrology, 12(3), 524-535. https://doi.org/10.2215/CJN.06180616